Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Amortizatization of Intangibles (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $9000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 97.7% year-over-year to $9000.0, compared with a TTM value of $410000.0 through Dec 2025, down 83.63%, and an annual FY2025 reading of $410000.0, down 83.63% over the prior year.
  • Amortizatization of Intangibles was $9000.0 for Q4 2025 at Karyopharm Therapeutics, down from $45000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q1 2023 and bottomed at -$664000.0 in Q1 2021.
  • Average Amortizatization of Intangibles over 5 years is $313850.0, with a median of $263000.0 recorded in 2022.
  • The sharpest move saw Amortizatization of Intangibles tumbled 5433.33% in 2021, then skyrocketed 2602.22% in 2023.
  • Year by year, Amortizatization of Intangibles stood at -$138000.0 in 2021, then skyrocketed by 436.23% to $464000.0 in 2022, then surged by 120.04% to $1.0 million in 2023, then plummeted by 61.61% to $392000.0 in 2024, then plummeted by 97.7% to $9000.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for KPTI at $9000.0 in Q4 2025, $45000.0 in Q3 2025, and $120000.0 in Q2 2025.